|Table of Contents|

Research progress of chemotherapy combined with anti-PD-(L)1 treatment in advanced triple-negative breast cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 06
Page:
1156-1161
Research Field:
Publishing date:

Info

Title:
Research progress of chemotherapy combined with anti-PD-(L)1 treatment in advanced triple-negative breast cancer
Author(s):
LIU Jiajing1; HUANG Guichun2; WANG Wenyi3; GU Jun1; 3
1.Department of General Surgery,Jinling Hospital of Nanjing Medical University,Jiangsu Nanjing 210002,China;2.Department of Medical Oncology;3.Department of General Surgery,Jinling Hospital Affiliated to Medical School of Nanjing University,Jiangsu Nanjing 210002,China.
Keywords:
triple negative breast cancer; chemotherapy; immune checkpoint inhibitors; tumor microenvironment; tumor immunity
PACS:
R737.9
DOI:
10.3969/j.issn.1672-4992.2023.06.035
Abstract:
Breast cancer is currently the highest incidence of female malignancy in China,of which 15%~20% are triple-negative breast cancer (TNBC).The overall prognosis of breast cancer is good,but the degree of TNBC malignancy is high,and the treatment methods are few,resulting in a poor clinical prognosis in patients with advanced TNBC.With the advent of immune checkpoint inhibitors (ICIs) in recent years,immunotherapy ［mainly PD-(L)1 monoclonal antibody］has become an alternative treatment for patients with TNBC.Current clinical data show that PD-(L)1 monoclonal antibody monotherapy in TNBC is not efficient while chemotherapy combined with PD-(L)1 monoclonal antibody can bring better response rates and prognosis to TNBC patients.The synergistic mechanism of chemotherapy with PD-(L)1 monoclonal antibody is currently unclear,limiting the use of chemotherapy combined with PD-(L)1 monoclonal antibody in TNBC.In this paper,the research progress of chemotherapy combined with PD-(L)1 monoclonal antibody in advanced TNBC is reviewed from three perspectives:Effects of chemotherapy on tumor immune microenvironment,effects of PD-(L)1 monoclonal antibody on tumor immune microenvironment,and the interaction of chemotherapy and PD-(L)1 monoclonal antibody,respectively.This review could provide a reference for further improving the efficacy of chemotherapy plus PD-(L)1 monoclonal antibody in TNBC.

References:

［1］SUNG H,FERLAY J,SIEGEL RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries ［J］.CA:A Cancer Journal for Clinicians,2021,71(3):209-249.
［2］CORTES J,CESCON DW,RUGO HS,et al.Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355):A randomised,placebo-controlled,double-blind,phase 3 clinical trial ［J］.Lancet (London,England),2020,396(10265):1817-1828.
［3］SCHMID P,CORTES J,PUSZTAI L,et al.Pembrolizumab for early triple-negative breast cancer ［J］.The New England Journal of Medicine,2020,382(9):810-821.
［4］MITTENDORF EA,ZHANG H,BARRIOS CH,et al.Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031):A randomised,double-blind,phase 3 trial ［J］.Lancet (London,England),2020,396(10257):1090-1100.
［5］SCHMID P,RUGO HS,ADAMS S,et al.Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable,locally advanced or metastatic triple-negative breast cancer (IMpassion130):Updated efficacy results from a randomised,double-blind,placebo-controlled,phase 3 trial ［J］.The Lancet Oncology,2020,21(1):44-59.
［6］ADAMS S,LOI S,TOPPMEYER D,et al.Pembrolizumab monotherapy for previously untreated,PD-L1-positive,metastatic triple-negative breast cancer:Cohort B of the phase II KEYNOTE-086 study ［J］.Annals of Oncology,2019,30(3):405-411.
［7］ADAMS S,SCHMID P,RUGO HS,et al.Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer:Cohort A of the phase II KEYNOTE-086 study ［J］.Annals of Oncology,2019,30(3):397-404.
［8］LIU J,LIU Q,LI Y,et al.Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer:An open-label phase II trial ［J］.Journal for Immunotherapy of Cancer,2020,8(1):e000696.
［9］HANAHAN D.Hallmarks of cancer:New dimensions ［J］.Cancer Discovery,2022,12(1):31-46.
［10］ANICHINI A,PEROTTI VE,SGAMBELLURI F,et al.Immune escape mechanisms in non small cell lung cancer ［J］.Cancers,2020,12(12):3605.
［11］ZHANG H,DAI Z,WU W,et al.Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer ［J］.Journal of Experimental & Clinical Cancer Research:CR,2021,40(1):184.
［12］ADAMS S,GATTI-MAYS ME,KALINSKY K,et al.Current landscape of immunotherapy in breast cancer:A review ［J］.JAMA Oncology,2019,5(8):1205-1214.
［13］NANDA R,CHOW LQ,DEES EC,et al.Pembrolizumab in patients with advanced triple-negative breast cancer:Phase Ib KEYNOTE-012 study ［J］.Journal of Clinical Oncology,2016,34(21):2460-2467.
［14］RUGO HS,DELORD JP,IM SA,et al.Safety and antitumor activity of pembrolizumab in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer ［J］.Clinical Cancer Research,2018,24(12):2804-2811.
［15］DIRIX LY,TAKACS I,JERUSALEM G,et al.Avelumab,an anti-PD-L1 antibody,in patients with locally advanced or metastatic breast cancer:A phase 1b JAVELIN solid tumor study ［J］.Breast Cancer Research and Treatment,2018,167(3):671-686.
［16］MILES D,GLIGOROV J,ANDRE F,et al.Primary results from IMpassion131,a double-blind,placebo-controlled,randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer ［J］.Annals of Oncology,2021,32(8):994-1004.
［17］VITO A,SALEM O,EL-SAYES N,et al.Immune checkpoint blockade in triple negative breast cancer influenced by B cells through myeloid-derived suppressor cells ［J］.Communications Biology,2021,4(1):859.
［18］DENKERT C,VON MINCKWITZ G,DARB-ESFAHANI S,et al.Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer:A pooled analysis of 3771 patients treated with neoadjuvant therapy ［J］.The Lancet Oncology,2018,19(1):40-50.
［19］XIAO Y,MA D,ZHAO S,et al.Multi-omics profiling reveals distinct microenvironment characterization and suggests immune escape mechanisms of triple-negative breast cancer ［J］.Clinical Cancer Research,2019,25(16):5002-5014.
［20］VOORWERK L,SLAGTER M,HORLINGS HM,et al.Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade:The TONIC trial ［J］.Nature Medicine,2019,25(6):920-928.
［21］GALLUZZI L,SENOVILLA L,ZITVOGEL L,et al.The secret ally:Immunostimulation by anticancer drugs ［J］.Nature Reviews Drug Discovery,2012,11(3):215-233.
［22］MARTINS I,KEPP O,SCHLEMMER F,et al.Restoration of the immunogenicity of cisplatin-induced cancer cell death by endoplasmic reticulum stress ［J］.Oncogene,2011,30(10):1147-1158.
［23］PARK YH,LAL S,LEE JE,et al.Chemotherapy induces dynamic immune responses in breast cancers that impact treatment outcome ［J］.Nature Communications,2020,11(1):6175.
［24］OSUNA-GOMEZ R,ARQUEROS C,GALANO C,et al.Effector mechanisms of CD8+HLA-DR+ T cells in breast cancer patients who respond to neoadjuvant chemotherapy ［J］.Cancers,2021,13(24):6167.
［25］PRINCIPE DR,KAMATH SD,KORC M,et al.The immune modifying effects of chemotherapy and advances in chemo-immunotherapy ［J］.Pharmacology & Therapeutics,2022,236:108111.
［26］VOLK-DRAPER L,HALL K,GRIGGS C,et al.Paclitaxel therapy promotes breast cancer metastasis in a TLR4-dependent manner ［J］.Cancer Res,2014,74(19):5421-5434.
［27］CUBAS R,MOSKALENKO M,CHEUNG J,et al.Chemotherapy combines effectively with anti-PD-L1 treatment and can augment antitumor responses ［J］.Journal of Immunology (Baltimore,Md:1950),2018,201(8):2273-2286.
［28］ZHU WY,JIN XY.A narrative review of combination therapy of PD-1/PD-L1 blockade with standard approaches for the treatment of breast cancer:Clinical application and immune mechanism ［J］.ANNALS OF PALLIATIVE MEDICINE,2021,10(9):10075-10082.
［29］GILAD Y,ELIAZ Y,YU Y,et al.Drug-induced PD-L1 expression and cell stress response in breast cancer cells can be balanced by drug combination ［J］.Scientific Reports,2019,9(1):15099.
［30］GOTO W,KASHIWAGI S,ASANO Y,et al.Eribulin promotes antitumor immune responses in patients with locally advanced or metastatic breast cancer ［J］.Anticancer Research,2018,38(5):2929-2938.
［31］UEDA S,SAEKI T,TAKEUCHI H,et al.In vivo imaging of eribulin-induced reoxygenation in advanced breast cancer patients:A comparison to bevacizumab ［J］.British Journal of Cancer,2016,114(11):1212-1218.
［32］DI CARO G,CORTESE N,CASTINO GF,et al.Dual prognostic significance of tumour-associated macrophages in human pancreatic adenocarcinoma treated or untreated with chemotherapy ［J］.Gut,2016,65(10):1710-1720.
［33］GELLER LT,BARZILY-ROKNI M,DANINO T,et al.Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine ［J］.Science,2017,357(6356):1156-1160.
［34］VINCENT J,MIGNOT G,CHALMIN F,et al.5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity ［J］.Cancer Res,2010,70(8):3052-3061.
［35］ROSELLI M,CEREDA V,DI BARI MG,et al.Effects of conventional therapeutic interventions on the number and function of regulatory T cells ［J］.Oncoimmunology,2013,2(10):e27025.
［36］SELIGER B,MASSA C.Immune therapy resistance and immune escape of tumors ［J］.Cancers,2021,13(3):551.
［37］BLANK C,GAJEWSKI TF,MACKENSEN A.Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion:Implications for tumor immunotherapy ［J］.Cancer Immunology,Immunotherapy:CII,2005,54(4):307-314.
［38］RUSSELL BL,SOOKLAL SA,MALINDISA ST,et al.The tumor microenvironment factors that promote resistance to immune checkpoint blockade therapy ［J］.Frontiers in Oncology,2021,11:641428.
［39］DURAISWAMY J,FREEMAN GJ,COUKOS G.Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer ［J］.Cancer Research,2013,73(23):6900-6912.
［40］HARTLEY GP,CHOW L,AMMONS DT,et al.Programmed cell death ligand 1 (PD-L1) signaling regulates macrophage proliferation and activation ［J］.Cancer Immunology Research,2018,6(10):1260-1273.
［41］SAMANTA D,PARK Y,NI X,et al.Chemotherapy induces enrichment of CD47(+)/CD73(+)/PDL1(+) immune evasive triple-negative breast cancer cells ［J］.Proceedings of the National Academy of Sciences of the United States of America,2018,115(6):E1239-E1248.
［42］李洪涛,李昊天,罗云飞,等.卡培他滨联合多西他赛对乳腺癌肝转移患者肠道菌群、肝功能及临床预后的影响分析 ［J］.世界华人消化杂志，2019,27(11):688-693. LI HT,LI HT,LUO YF,et al.Effect of capecitabine combined with docetaxel on intestinal flora,liver function,and clinical prognosis in patients with breast cancer liver metastases ［J］.World Chinese Journal of Digestology,2019,27(11):688-693.
［43］SIVAN A,CORRALES L,HUBERT N,et al.Commensal bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy ［J］.Science (New York,NY),2015,350(6264):1084-1089.
［44］DAILLERE R,VETIZOU M,WALDSCHMITT N,et al.Enterococcus hirae and barnesiella intestinihominis facilitate cyclophosphamide-induced therapeutic immunomodulatory effects ［J］.Immunity,2016,45(4):931-943.
［45］WOJAS-KRAWCZYK K,KALINKA E,GRENDA A,et al.Beyond PD-L1 markers for lung cancer immunotherapy ［J］.International Journal of Molecular Sciences,2019,20(8):1915.
［46］CAO B,LI M,ZHA W,et al.Metabolomic approach to evaluating adriamycin pharmacodynamics and resistance in breast cancer cells ［J］.Metabolomics,2013,9(5):960-973.
［47］ZIDI O,SOUAI N,RAIES H,et al.Fecal metabolic profiling of breast cancer patients during neoadjuvant chemotherapy reveals potential biomarkers ［J］.Molecules (Basel,Switzerland),2021,26(8):2266.
［48］CHANG CH,QIU J,O' SULLIVAN D,et al.Metabolic competition in the tumor microenvironment is a driver of cancer progression ［J］.Cell,2015,162(6):1229-1241.
［49］LU L,XU X,ZHANG B,et al.Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs ［J］.Journal of Translational Medicine,2014,12:36.
［50］LIU S,CHEN S,YUAN W,et al.PD-1/PD-L1 interaction up-regulates MDR1/P-gp expression in breast cancer cells via PI3K/AKT and MAPK/ERK pathways ［J］.Oncotarget,2017,8(59):99901-99912.
［51］GHEBEH H,LEHE C,BARHOUSH E,et al.Doxorubicin downregulates cell surface B7-H1 expression and upregulates its nuclear expression in breast cancer cells:Role of B7-H1 as an anti-apoptotic molecule ［J］.Breast Cancer Research:BCR,2010,12(4):R48.
［52］XU S,TAO Z,HAI B,et al.miR-424(322) reverses chemoresistance via T-cell immune response activation by blocking the PD-L1 immune checkpoint ［J］.Nature Communications,2016,7:11406.

Memo

Memo:
National Natural Science Foundation of China(No.81472668); 国家自然科学基金（编号：81472668）;江苏省青年医学重点人才项目（编号：QNRC2016887）
Last Update: 1900-01-01